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Abstract
Purpose To assess the long-term outcomes and complica-
tions of patients with uveitis from juvenile idiopathic arthri-
tis (JIA) treated with adalimumab.
Methods Prospective interventional case series. All patients
who underwent treatment with adalimumab for JIA and
anterior uveitis were prospectively included in the study.
The anterior chamber inflammation was evaluated accord-
ing to the Standardization of Uveitis Nomenclature criteria.
Results Twenty-one patients (16 females, five males, 38 eyes)
were included in the study. Mean age of patients at referral
was 11.1±3.8 (5–17) years. Before initiation of treatment,
mean duration of arthritis was 7.0±5.5 (median, 6) months,
mean duration of uveitis was 7.0±4.4 (median, 7) months.
Oligoarticular arthritis was present in 15 cases (71 %), poly-
articular arthritis in six cases (28 %). After a mean follow-up
of 18.2±7.7 (9–41) months, resolution of anterior chamber
inflammation was obtained in 29/38 eyes (76 %). The anterior
uveitis flare rate during the 12 months prior to enrollment was
1.6 ± 0.4/year, and was reduced during adalimumab treat-
ment to 0.7±0.3/year (p<0.001). A significant decrease
of the number of relapses/month was present after onset of
treatment with adalimumab (0.18±0.2 before versus 0.02±0.1
after treatment onset, p<0.001). No significant correlation
was found between relapse number and age, sex, type of JIA
and doses of previous steroid treatment (p>0.05).
Conclusion Adalimumab showed to be effective and rela-
tively safe for treatment of JIA-associated uveitis.
Keywords Adalimumab, uveitis . Arthritis . Cataract .
Ocular hypertension . Intraocular lens . TNF-α
Introduction
Juvenile idiopathic arthritis (JIA) is the most common chronic
rheumatic disease in children [1, 2]. Uveitis has been reported
in 10 %–20 % of patients with juvenile idiopathic arthritis, and
may lead to significant ocular damage and even blindness [3,
4]. The time interval between arthritis and uveitis onset is the
main predictor of severe course uveitis in JIA. [5]. Tumor
necrosis factor-alpha (TNF-α) has been shown to play an
important role in the development of uveitis [6]. TNF-α block-
ers have been used to treat uveitis and juvenile idiopathic
arthritis, and especially uveitis associated with juvenile idio-
pathic arthritis in children who have failed conventional topical
and second-line disease-modifying antirheumatic drug therapy
[7, 8]. However, adequate data on the long-term safety and
efficacy of the anti-TNFs are mainly for JIA patients with a
polyarticular course, and refer to etanercept and infliximab
[9–18]. A greater effectiveness of humanized monoclonal
TNF-α antibody adalimumab for uveitis compared with eta-
nercept has been shown [19, 20]. Herein, we evaluated the
long-term outcomes and complications of patients with uveitis
from JIA treated with adalimumab.
Methods
All patients who underwent treatment with adalimumab for
JIA were prospectively included in the study. IRB approval
was obtained, the ethics committee of the University Feder-
ico II granted the approval for this study, and the patients
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and/or their guardians gave their informed consent to obtain
the data. Inclusion criteria were diagnosis of JIA based on
International League Against Rheumatology (ILAR) diagnos-
tic criteria [21] before 16 years of age, non-responsiveness
and/or non-compliance to topical therapy and second-line
agents, and non-responsiveness and/or non-compliance to a
different biologic drug. A pediatric rheumatologist evaluated
juvenile idiopathic arthritis at 3- to 4-month intervals, depend-
ing on the severity of the disease. On each visit, the number of
active and swollen joints as well as erythrocyte sedimentation
rate and laboratory tests (routine blood examination, anti-
nuclear antibodies, extractable nuclear antigen antibodies,
immunoglobulins, and C-reactive protein) for drug safety
were assessed. Improvement of arthritis was assessed using
the American College of Rheumatology (ACR) Pediatric 30,
50, and 70 criteria [22].
Ophthalmic evaluation included best-corrected visual acu-
ity (BCVA), intraocular pressure (IOP) measurement by
applanation tonometry, anterior segment biomicroscopy, eval-
uation of cells and flare, fundus ophthalmoscopy. Fluorescein
angiography, optical coherence tomography, and echography
were performed when necessary. Ophthalmic examination
was performed at monthly intervals. In case of relapse,
patients were seen at 7- to 15-day intervals. The activity of
the anterior chamber inflammation was evaluated according to
the Standardization of Uveitis Nomenclature (SUN) criteria,
where the activity of anterior chamber inflammation was
graded from 0 to 4 (grade/cells in field: 0 = <1, 0.5+ = 1–5,
1+ = 6–15, 2+ = 16–25, 3+ = 26–50, 4+ = >50) [23]. An
improved activity was defined as either a two-step decrease in
the level of inflammation or a decrease to inactive (grade 0), a
relapse as either a two-step increase in the level of inflamma-
tion or an increase to the maximum grade (4+), a stabilization
as a change of <2 steps. If one eye improved, but the other eye
worsened, the interpretation was increased activity. The flare
in uveitis was defined as an episode with worsening activity in
the anterior chamber inflammation during the follow-up. The
number of flares was assessed from 1 year before adalimumab
to baseline and from baseline to the end of the follow-up. The
patients were initially given a standard dose of adalimumab
subcutaneously every 2 weeks (40 mg to 18/20 patients, and
20 mg to two patients weighing <30 kg), and according to
clinical response, up to a frequency of 24 mg/m2 at 7-day
intervals. Treatment was continued throughout the study pe-
riod. Ocular hypertension was defined as intraocular pressure
>21 on more than one examination. In patients with sec-
ondary cataract, after complete removal of the cataract,
posterior capsulorexis and anterior vitrectomy were per-
formed. At least 3 months of quiescence were requested
prior to cataract surgery. Corticosteroids orally, in doses
of 1–2 mg/kg/day, and topically were used before and
after surgery. Postoperatively, dexamethasone was given
eight times per day and a combination of cyclopentolate
and phenylephrine three times per day, followed by a
slow taper on an individual basis. When removal of
secondary cataract was necessary, a hydrophobic acrylic
IOL with polymethyl methacrylate haptics (VA-60BB;
Hoya Corporation) was implanted into the capsular bag.
All statistical analyses were carried out with statistical
software (STATAversion 11, STATA Corp., College Station,
TX, USA). The differences between the number of relapses
before and during adalimumab therapy were compared us-
ing Cox regression. The differences between the patient
characteristics on adalimumab with good or poor outcome
were compared using the Mann–Whitney U-test (continuous
variables) or Fisher’s exact test (category variables). The
5 % significance level was used in all tests.
Results
Twenty-one patients (16 females, five males, 38 eyes)
were enrolled during 24 months. Baseline characteristics
of the 21 patients are showed in Table 1. Mean age of
patients at referral to our visit was 11.1±3.8 (5–17)
years. Mean duration of arthritis before starting treat-
ment with adalimumab was 7.0±5.5 (median, 6)
months, mean duration of uveitis was 7.0±4.4 (median,
7) months. Oligoarticular arthritis was present in 15
cases (71.4 %), polyarticular arthritis in six cases
(28.6 %). In ten patients (47.6 %), the arthritis was
diagnosed 2.5±2.0 months before the diagnosis of uve-
itis was made. In seven cases (33.4 %), uveitis was
diagnosed 3.5±2.2 months before arthritis, while in four
cases (19.0 %) arthritis and uveitis were diagnosed at
the same time (11.7±2.6 months). Nine of 21 children
(42.8 %) were antinuclear antibody positive (5/12 oli-
goarticular, 41.6 %; 2/6 poliarticular, 33.3 %). Treat-
ment with adalimumab was started to treat the ocular
disease in 12 patients (57 %), while in nine cases
(43 %) it was administered due to relapses of uveitis
and arthritis.
Outcomes
Mean follow-up after starting adalimumab was 18.2±7.7
(9–41)months. Nine months after starting therapy and dur-
ing remaining follow-up, resolution of anterior chamber
inflammation was obtained in 29/38 eyes (76 %), while
6/38 eyes (16 %) remained stable during follow up, without
relapse, and in 3/38 eyes (8 %) inflammation increased.
Mean BCVA improved from 20/50 at baseline to 20/40 at
9-month visit, and to 20/32 at 2-year visit, 3-year visit and at
last visit. Overall, six patients showed a relapse of the
uveitis 5.1±2.3 months after onset of treatment with adali-
mumab, and in two cases a concomitant active arthritis was
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present. One of them stopped treatment. In the remaining 15
patients, an improvement of anterior chamber inflammation
was present 6±3.2 weeks (2–12) after treatment onset. The
anterior uveitis flare rate during the 12 months prior to enroll-
ment was 1.6 ± 0.4/year, and was reduced during adalimumab
treatment to 0.7±0.3/year (p<0.001). No differences were
present between treatment with adalimumab alone and in
association with methotrexate with regard to outcomes and
relapses. A significant decrease of the number of relapses/
month was present after onset of treatment with adalimumab
(0.18±0.2 before versus 0.02±0.1 after treatment onset,
p<0.001). No significant correlation was found between re-
lapse number and age, sex, type of JIA, and steroid doses
(p>0.05). All six patients who showed relapses presented with
a longer history of uveitis (9.2±2.1 vs 6.1±2.6 months,
p=0.001) and a wider articular involvement at treatment on-
set. All nine patients presenting with uveitis and arthritis at
onset of treatment showed an ACR 50 response at 12-month
visit. Arthritis resolved in 6/9 cases (66 %), remained stable in
1/9 case (11%), and worsened in 2/9 cases (22%). In all of the
three cases that did not show improvement of arthritis, a
diagnosis of polyarticular JIAwas made.
Previous treatments
All patients had undergone oral steroid treatment before ada-
limumab treatment. Fourteen patients had been treated with
methotrexate (15 mg/m2 up to 20 mg weekly, in absence of
side-effects). Of them, two patients had to stop methotrexate
therapy because of intolerance, while treatment is still ongoing
in association with adalimumab in 12 cases. Eleven patients
(52.4 %) had been previously treated with a different biologic
drug (etanercept in three cases, infliximab in six cases, eta-
nercept and infliximab in two cases) but treatment had to be
stopped because of low effectiveness or because of side-
effects (1/5 on etanercept, 2/8 on infliximab). In one case,
methotrexate, ciclosporin, salazopirin, etanercept, and inflix-
imab had been administered before adalimumab. In this case,


















1 7 2 f oligo 6/5 Dex NR-adr Uv ADA
2 9 2 f oligo 2/7 Dex NR-adr Uv ADA
3 17 2 f oligo 15/10 Dex/MTX NR:uv Uv ADA
4 7 2 f oligo 4/3 Dex/MTX NR:art/uv Art + Uv ADA + MTX
5 17 2 f poly 16/14 Dex/MTX/ETA NR:art/uv Art + Uv ADA + MTX
6 9 2 f poly 1/7 Dex/MTX NR-adr Uv ADA + MTX
7 11 2 m oligo 10/4 Dex NR-adr Uv ADA
8 9 2 f oligo 3/4 Dex/MTX/INF NR:uv Uv ADA + MTX
Adr:glauc
9 9 2 f oligo 1/7 Dex/INF NR:uv Uv ADA
10 10 1 f oligo 7/2 Dex/MTX NR:Art/uv Art + uv ADA + MTX
11 13 2 f oligo 9/9 Dex/MTX NR:uv Uv ADA + MTX
12 15 2 m oligo 14/14 Dex/MTX/ETA NR:art/uv Art + uv ADA + MTX
Adr:tub
13 13 2 m poly 3/2 Dex/MTX/
ETA/INF
NR:uv Uv ADA
14 5 2 m oligo 1/3 Dex NR-adr Uv ADA
15 17 1 f oligo 14/14 Dex/MTX NR:art/uv Art + uv ADA + MTX
16 12 1 m oligo 10/8 Dex/MTX/ETA NR:uv Art + uv ADA
17 17 2 f poly 16/15 Dex/MTX/
Cicl/ETA/INF
adr/adr/NR/adr/in Art + uv ADA + MTX
18 6 1 f oligo 1/2 Dex/INF NR:uv Uv ADA
19 11 2 f oligo 1/5 Dex/MTX/INF NR:uv Uv ADA + MTX
20 8 2 f poly 3/2 Dex/MTX/INF NR:art/uv Art + uv ADA + MTX
21 11 2 f poly 10/10 Dex/INF NR:art/uv Art + uv ADA
ADA adalimumab; MTX methotrexate; INF infliximab; ETA etanercept; dex dexamethasone; Art, art arthritis; Oligo oligoathritis; Poly polyarthrits;
uv uveitis; NR no/poor response; adr, adverse drug reaction
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even adalimumab was ineffective and now the patient is on
abatacept [24].
Coexisting therapies
In 11 patients (52.4 %), concomitant methotrexate was ad-
ministered. Two out of eight patients (25 %) who failed
infliximab were not treated with concomitant methotrexate.
In all patients undergoing coexisting therapies, the dosage of
coexisting drug was lowered after a mean period of 1.2±
0.6 weeks, and in no case was an increase necessary. In 2/11
cases (18.2 %), treatment with methotrexate was reduced due
to side-effects, but a constant clinical improvement was pres-
ent. Topical steroids were reduced in 2/7 cases (28.6 %) and
were stopped in 5/7 patients (71.4 %). In three out of four
patients, oral steroids were stopped, while in one patient,
continuation of oral steroidal treatment was necessary due to
the aggressive course of the systemic and ocular disease.
Complications and side-effects
Before inclusion in the study, 15 patients (71 %) had shown
complications of uveitis. Nine cases (42.8 %) had developed
secondary cataract and had undergone cataract extraction. Of
them, in seven cases intraocular lens (IOL) was implanted, while
in two cases IOLwas not inserted. After amean follow up of 8.3
±3.1 months, secondary ocular hypertension developed in all of
the seven patients who underwent IOL implantation, while it did
not develop when IOL implantation was not performed. Of the
seven patients who developed secondary ocular hypertension,
four patients underwent trabeculectomy with mithomicin C, and
are still on antiglaucomatous treatment. The remaining three
patients are on antiglaucomatous treatment with brimonidine
0.2 %, timolol 0.5 %, and brinzolamide 10 mg/ml.
Twelve patients (57 %) had developed uveitic ocular
hypertension before inclusion in the study, and were on
antiglaucomatous treatment at our first observation. Of
them, five patients (42 %) had been treated with basal
iridotomy and trabeculectomy. Four patients (19 %) had
developed band-shaped keratitis. Of them, two underwent
corneal disepithelization, ethylene-diaminetetraacetic acid
(EDTA) chelation, and bandage contact lens. In six cases
(28 %), a posterior involvement with macular edema was
present. Of them, two cases showed cystoid macular edema
since onset of the disease. A transient erythema was ob-
served in 2/21 cases (9.5 %), and improved in 5 days with-
out treatment.
Discussion
In this prospective study, we focused on adalimumab treat-
ment for uveitis specifically from JIA and following the
SUN criteria for improvement. Despite the small sample
size mainly due to the rarity of the disease, and despite
52.4 % of patients having had prior anti-TNF therapy,
nevertheless an improvement of the ocular symptoms was
observed in 76 % of cases, stabilization in 16 % of cases and
a relapse in 8 % of cases. Anterior uveitis flare rate reduced
significantly after starting adalimumab treatment. Few ret-
rospective studies have evaluated adalimumab for JIA-
associated uveitis. In a recent large series, 39 out of 131
patients with refractory uveitis treated with adalimumab
presented with JIA, and adalimumab showed to be well-
tolerated and helpful in decreasing inflammatory activity
[25]. In the study by Tynjälä et al., improvement was ob-
served in 35 % of cases only after 18.7 months [26]. This
low percentage may be due to the higher age of patients
(13.4 years versus 11.3 years in our study), to the longer
duration of uveitis before starting treatment with adalimu-
mab (8.7 years), and to previous treatment with anti-TNF-α
drugs in 95 % of cases. In the study by Kotaniemi et al.,
improvement of uveitis was observed in 58 % of 54 patients
with JIA-associated uveitis [27]. This difference with our
study may be due to the different sample size.
Several studies evaluated adalimumab for treatment of
chronic uveitis not specifically associated with JIA.
Vazquez-Cobian et al. reported an improvement of ocular
symptoms in 81 % of cases, although they included both
JIA-associated and idiopathic uveitis, and their definition of
improvement did not follow SUN criteria [28]. Biester et al.
reported an improvement of the ocular inflammation in
89 % of 18 patients (17 had juvenile idiopathic arthritis,
one was without detectable underlying disease) [19]. How-
ever, in their study, improvement for uveitis was only de-
fined as a reduction of at least 2+ cells in the anterior cells.
Furthermore, age of patients at initiation of treatment was
not clearly stated. In a recent prospective study over 3 years
of treatment, Simonini et al. showed that adalimumab is
more effective than infliximab in maintaining remission of
chronic childhood uveitis in 16 patients (12 with JIA, three
with idiopathic uveitis, and one with Behçet’s disease) [29].
As in previous studies, serious side-effects and adverse
events were absent [19, 28]. In adult studies, adalimumab
has demonstrated an acceptable safety profile, and the rate
of serious infections has also been low; 0.02/patient-year
[30]. Adalimumab seems to cause fewer hypersensitivity
reactions than infliximab, at least with the doses given in
our patient cohort.
After cataract extraction, secondary ocular hypertension
never developed when IOL implantation was not performed.
On the other hand, all of the seven patients who underwent
IOL implantation developed ocular hypertension. Ocular
hypertension is a common complication of juvenile rheu-
matoid arthritis (JRA)-associated uveitis [31, 32], and in this
series ocular hypertension had developed preoperatively in
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three eyes. However after cataract extraction, ocular hy-
pertension developed in all eyes that underwent IOL
implantation, while it did not develop when IOL im-
plantation was not performed. Of the seven eyes that
developed high IOP, four were resistant to topical anti-
glaucomatous treatment, and needed hypotonising sur-
gery. Despite the small population, our results may
suggest that patients with uveitis, and especially those
with chronic systemic disease, are at an especially high
risk of increased IOP and uncontrolled inflammation
after IOL implantation.
In all patients undergoing coexisting therapies, the dos-
age of coexisting drug was lowered, and in no case was an
increase necessary. Despite being costly, adalimumab could
therefore represent an adjuvant therapy for the treatment of
uveitis, and our results probably confirm the effectiveness
and relatively good safety of adalimumab for treatment of
JIA-associated uveitis.
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